IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
